Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of Directors [Yahoo! Finance]
Elevation Oncology, Inc. - Common stock (ELEV)
Company Research
Source: Yahoo! Finance
of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the appointments of Julie Cherrington , Ph.D. and Alan Sandler , M.D., to its Board of Directors. "We are thrilled to welcome Julie and Alan as Elevation Oncology's newest directors," said Steve Elms , Chairman of Elevation Oncology. "Both are extremely experienced drug developers, who have contributed to the advancement and approval of multiple targeted therapies for the treatment of cancer. On behalf of the Board, I look forward to Julie and Alan's many insights into both clinical and regulatory strategy as Elevation Oncology continues to advance its pipeline of differentiated, potentially best-in-class antibody-drug conjugate (ADC) therapies." "I am excited to lend my expertise in drug development and company building to help Elevation Oncology advance selective cancer therapies to improve the care and treatment of patients with solid tumors," sai
Show less
Read more
Impact Snapshot
Event Time:
ELEV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELEV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELEV alerts
High impacting Elevation Oncology, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ELEV
News
- Elevation Oncology: Mid-2024 EO-3021 Data Could Get Ball Rolling [Seeking Alpha]Seeking Alpha
- Elevation Oncology, Inc. (NASDAQ: ELEV) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $8.00 price target on the stock.MarketBeat
- Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements [Yahoo! Finance]Yahoo! Finance
- Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business AchievementsPR Newswire
- Elevation Oncology: Continuing To Seek Footing As It Climbs (Rating Upgrade) [Seeking Alpha]Seeking Alpha
ELEV
Sec Filings
- 5/2/24 - Form S-3
- 5/2/24 - Form 8-K
- 5/2/24 - Form 10-Q
- ELEV's page on the SEC website